Investors & Media

What's new.

Press releases

Press releases.

July 30th 2025

Immutep Quarterly Activities Report Q4 FY25

July 29th 2025

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

July 28th 2025

Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

more

Investor updates

Investor updates.

April 23rd 2025

Investor Update - April 2025

November 26th 2024

Investor Update - November 2024

February 21st 2024

Investor Update - February 2024

more

Analyst reports

Analyst reports.

Wilsons - IMP761 | Can I&I success fund I-O upside? Maintain Overweight, A$1.20 TP (Analysts: Dr Shane Storey and Dr Lisa Worley)

July 11th 2025

Jefferies - Efti/Pembro Looks Good vs. Other Combos and Other Therapies in NSCLC and HNSCC; Rated BUY, PT A$2.10 (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

June 23rd 2025

Baird - Updated Phase 1 Safety/Efficacy HV Data for IMP761 (LAG-3) for Autoimmune; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)

For a copy of this research report please contact your Baird advisor

more